Code of practice needed for samples donated by trial participants

Robert Coleman; Arlene Chan; Carlos Barrios; David Cameron; Luis Costa; Mitch Dowsett; David Harrison; Anthony Howell; Denis Lacombe; Mairead MacKenzie; Miguel Martin; Stuart McIntosh; Adrienne Morgan; Martine Piccart; Tanja Spanic

doi:10.1016/S1470-2045(22)00059-6

Code of practice needed for samples donated by trial participants

Robert Coleman, Arlene Chan, Carlos Barrios, David Cameron, Luis Costa, Mitch Dowsett, David Harrison, Anthony Howell, Denis Lacombe, Mairead MacKenzie, Miguel Martin, Stuart McIntosh, Adrienne Morgan, Martine Piccart, Tanja Spanic

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e89-e90
Journal	The Lancet Oncology
Volume	23
Issue number	3
DOIs	https://doi.org/10.1016/S1470-2045(22)00059-6
Publication status	Published - Mar 2022

Access to Document

10.1016/S1470-2045(22)00059-6

Cite this

@article{8ba2c941ef6d4dee8044505dc43b6338,

title = "Code of practice needed for samples donated by trial participants",

author = "Robert Coleman and Arlene Chan and Carlos Barrios and David Cameron and Luis Costa and Mitch Dowsett and David Harrison and Anthony Howell and Denis Lacombe and Mairead MacKenzie and Miguel Martin and Stuart McIntosh and Adrienne Morgan and Martine Piccart and Tanja Spanic",

note = "Funding Information: RC received personal fees for speaking engagements and development of educational materials. CB's institution received grant and research support from Pfizer, Novartis, Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Roche/Genentech, Lilly, Sanofi, Taiho Pharmaceutical, Mylan, Merrimack, Merck, AbbVie, Astellas Pharma, BioMarin, Bristol-Myers Squibb, Daiichi Sankyo, Abraxis Biosciences, AB Science, Asana Biosciences, Medivation, Exelixis, ImClone Systems, LEO Pharma, Millennium, Merck KGaA, Shanghai Henlius Biotech, Polyphor, and PharmaMar. CB was on the advisory board or consulted for, received payment or honoraria, and received support for attending meetings for Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, Bayer, MSD, AstraZeneca, Zodiac, Lilly, Sanofi, and Amgen. MD received grants or contacts to their institution for Pfizer and Lilly; received consulting fees from Radius, G1, AbbVie, H3 Biomedicines, Lilly, Zentalis, Roche, Besins, AstraZeneca, and ROVI; and received payment or honoraria from Nanostring. SI received academic grant funding from the National Institute for Health Research; international research funding from Novartis; consulting fees to their institution from Lilly and Roche; institutional payment or honoraria from Roche; support for attending meetings from Roche and Lilly; and was the chair for the Breast Research Group with the National Cancer Research Institute. RC, AC, and CB were members of the D-CARE Trial Steering Committee; RC and LC were members of the D-CARE biomarker subcommittee and AH was a member of the D-CARE data monitoring and safety committee. AH is on the German Breast Group Independent Data Monitoring Committee (multiple studies), Bristol Myers Squibb (CA2097FL), and Pfizer. All other authors declare no competing interests.",

year = "2022",

month = mar,

doi = "10.1016/S1470-2045(22)00059-6",

language = "English",

volume = "23",

pages = "e89--e90",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "The Lancet",

number = "3",

}

TY - JOUR

T1 - Code of practice needed for samples donated by trial participants

AU - Coleman, Robert

AU - Chan, Arlene

AU - Barrios, Carlos

AU - Cameron, David

AU - Costa, Luis

AU - Dowsett, Mitch

AU - Harrison, David

AU - Howell, Anthony

AU - Lacombe, Denis

AU - MacKenzie, Mairead

AU - Martin, Miguel

AU - McIntosh, Stuart

AU - Morgan, Adrienne

AU - Piccart, Martine

AU - Spanic, Tanja

N1 - Funding Information: RC received personal fees for speaking engagements and development of educational materials. CB's institution received grant and research support from Pfizer, Novartis, Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Roche/Genentech, Lilly, Sanofi, Taiho Pharmaceutical, Mylan, Merrimack, Merck, AbbVie, Astellas Pharma, BioMarin, Bristol-Myers Squibb, Daiichi Sankyo, Abraxis Biosciences, AB Science, Asana Biosciences, Medivation, Exelixis, ImClone Systems, LEO Pharma, Millennium, Merck KGaA, Shanghai Henlius Biotech, Polyphor, and PharmaMar. CB was on the advisory board or consulted for, received payment or honoraria, and received support for attending meetings for Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, Bayer, MSD, AstraZeneca, Zodiac, Lilly, Sanofi, and Amgen. MD received grants or contacts to their institution for Pfizer and Lilly; received consulting fees from Radius, G1, AbbVie, H3 Biomedicines, Lilly, Zentalis, Roche, Besins, AstraZeneca, and ROVI; and received payment or honoraria from Nanostring. SI received academic grant funding from the National Institute for Health Research; international research funding from Novartis; consulting fees to their institution from Lilly and Roche; institutional payment or honoraria from Roche; support for attending meetings from Roche and Lilly; and was the chair for the Breast Research Group with the National Cancer Research Institute. RC, AC, and CB were members of the D-CARE Trial Steering Committee; RC and LC were members of the D-CARE biomarker subcommittee and AH was a member of the D-CARE data monitoring and safety committee. AH is on the German Breast Group Independent Data Monitoring Committee (multiple studies), Bristol Myers Squibb (CA2097FL), and Pfizer. All other authors declare no competing interests.

PY - 2022/3

Y1 - 2022/3

UR - http://www.scopus.com/inward/record.url?scp=85125352929&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(22)00059-6

DO - 10.1016/S1470-2045(22)00059-6

M3 - Letter

C2 - 35240091

AN - SCOPUS:85125352929

SN - 1470-2045

VL - 23

SP - e89-e90

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 3

ER -

Code of practice needed for samples donated by trial participants

Access to Document

Other files and links

Cite this